Home›Stocks›BCAX

BCAX — structural market context

Bicara Therapeutics Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 22. Each line shows the earlier value, the later value and their dates.

Price

Close $17.61 (Oct 22) vs $17.91 (Oct 21): −1.68%.

Volume

0.95× its 20-session average (856K) on Oct 22.

Includes pre- and post-market trading.

Short interest

Short interest 10.7M shares (settlement Sep 30) vs 11.2M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 5 days with fails, largest 3K shares on Sep 18.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 1 day with fails, largest 2K shares on Sep 3.

No new publication in this window.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

BCAX events and their magnitude

Latest SEC filing in the event study

Form 4 · other · filed 2026-09-10 · View on sec.gov ↗

…

Open the Event Study →

BCAX short interest & days to cover

SHARES SHORT
10.7M
% OF FLOAT
29.0%
DAYS TO COVER
14.2
CHANGE VS PRIOR
-4.5%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (23d ago)

BCAX fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-28 · 25d326$19.21
2026-09-25 · 28d326$19.78
2026-09-18 · 35d3K$22.59

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

BCAX insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 2 sales

InsiderTypeSharesValueFiled
Cohlhepp Ryan · director, officer: President, COO & Interim CEOSale (S)3K$81K2026-09-10
Cohlhepp Ryan · director, officer: President, COO & Interim CEOSale (S)14K$320K2026-09-10

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

BCAX analyst ratings

FirmActionRatingPublished
Morgan StanleyholdOverweight2026-10-20
Morgan Stanleyprice_target—2026-10-20
HSBCdowngradeEqual-Weight2026-09-22
Cantor FitzgeraldholdOverweight2026-09-10
CitigroupholdMarket Outperform2026-08-21

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is BCAX's short interest?
As of the FINRA settlement date 2026-09-30, BCAX had 10.7M shares sold short — 29.0% of its float, with 14.2 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying BCAX?
In the last 12 months of SEC Form 4 filings, BCAX recorded 0 insider purchases and 2 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about BCAX?
The most recent action: Morgan Stanley hold to Overweight on 2026-10-20. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell BCAX?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with B

B · Barrick Mining CorporationBAM · Brookfield Asset Management LtBAND · Bandwidth Inc.BBNX · Beta Bionics, Inc.BE · Bloom Energy CorporationBEAM · Beam Therapeutics Inc.All B →

BCAX: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.